RxDoctor Payments Data

Andrew Cougill, MD

Family Medicine · Indianapolis, INNPI 1508959487

Payments from drug & device makers

$767in general payments, 2019–2025

Across 50 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$145
  • GSK$126
  • Pfizer$119
  • Lilly USA, LLC$70
  • Novo Nordisk$59
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$45
  • plus $203 from 10 others

What the payments were for

  • Food & beverage$767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$767 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$73,679
Medicare patients
204
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide68$86,119
JanuviaSitagliptin Phosphate62$68,703
JardianceEmpagliflozin24$43,522
TrulicityDulaglutide17$43,186
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$30,915
Inderal LaPropranolol Hcl13$27,082
XareltoRivaroxaban22$25,117
Tresiba Flextouch U-200Insulin Degludec21$22,616
TradjentaLinagliptin16$22,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,597
OzempicSemaglutide18$16,861
EliquisApixaban11$11,860
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$11,277
Breo ElliptaFluticasone/Vilanterol12$11,094
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$9,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$70$129,30585 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Shingrix$126$68,522112 claims
Novo NordiskOzempic$59$16,86118 claims
PfizerEliquis$119$11,86011 claims
AbbVieSynthroid$13$1,56125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →